BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237. [PMID: 19307500 DOI: 10.1200/jco.2008.20.0238] [Cited by in Crossref: 449] [Cited by in F6Publishing: 223] [Article Influence: 34.5] [Reference Citation Analysis]
Number Citing Articles
1 Johnson B, Vanderwalde A, Javadi N, Feldman R, Reddy SB. Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. J Gastrointest Oncol 2016;7:E6-E12. [PMID: 27034805 DOI: 10.3978/j.issn.2078-6891.2015.091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
3 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
4 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Van Cutsem E, Li CP, Nowara E, Aprile G, Moore M, Federowicz I, Van Laethem JL, Hsu C, Tham CK, Stemmer SM. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer. 2014;111:2067-2075. [PMID: 25247318 DOI: 10.1038/bjc.2014.494] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
6 Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, Patel SG, Wu N, Hindoyan A, Farrell JJ, Li X, Dawson DW, Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012;18:1352-63. [PMID: 22261810 DOI: 10.1158/1078-0432.CCR-11-1539] [Cited by in Crossref: 131] [Cited by in F6Publishing: 93] [Article Influence: 13.1] [Reference Citation Analysis]
7 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
8 Longo V, Brunetti O, Gnoni A, Cascinu S, Gasparini G, Lorusso V, Ribatti D, Silvestris N. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget 2016;7:58649-58. [PMID: 27462915 DOI: 10.18632/oncotarget.10765] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
9 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
10 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Siolas D, Morrissey C, Oberstein PE. The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials. J Pancreatol 2020;3:121-31. [PMID: 33133736 DOI: 10.1097/JP9.0000000000000052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681-689. [PMID: 23315099 DOI: 10.1007/s00432-012-1371-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
13 Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17:192-200. [PMID: 22250057 DOI: 10.1634/theoncologist.2011-0268] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
14 Sun S, Kim MJ, Dibwe DF, Omar AM, Athikomkulchai S, Phrutivorapongkul A, Okada T, Tsuge K, Toyooka N, Awale S. Anti-Austerity Activity of Thai Medicinal Plants: Chemical Constituents and Anti-Pancreatic Cancer Activities of Kaempferia parviflora. Plants (Basel) 2021;10:229. [PMID: 33503922 DOI: 10.3390/plants10020229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
16 Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol 2020;17:487-505. [PMID: 32393771 DOI: 10.1038/s41575-020-0300-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 37.5] [Reference Citation Analysis]
17 Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379 [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
18 Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
19 Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9:378-90. [PMID: 22525710 DOI: 10.1038/nrclinonc.2012.64] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 11.5] [Reference Citation Analysis]
20 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
21 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
22 Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32. [PMID: 20198462 DOI: 10.1208/s12248-010-9181-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
23 Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26. [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb] [Cited by in Crossref: 120] [Cited by in F6Publishing: 64] [Article Influence: 13.3] [Reference Citation Analysis]
24 Zhang Y, Kirane A, Huang H, Sorrelle NB, Burrows FJ, Dellinger MT, Brekken RA. Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer. Mol Cancer Res 2019;17:348-55. [PMID: 30333153 DOI: 10.1158/1541-7786.MCR-18-0427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M, Tanaka M. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol 2011;18:2381-7. [PMID: 21347785 DOI: 10.1245/s10434-011-1602-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
26 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
27 Rubinstein L, Leblanc M, Smith MA. More randomization in phase II trials: necessary but not sufficient. J Natl Cancer Inst 2011;103:1075-7. [PMID: 21709273 DOI: 10.1093/jnci/djr238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
28 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
29 Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906. [PMID: 24858820 DOI: 10.1007/s00228-014-1687-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
30 Bausch D, Pausch T, Krauss T, Hopt UT, Fernandez-del-Castillo C, Warshaw AL, Thayer SP, Keck T. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis. 2011;14:235-243. [PMID: 21442180 DOI: 10.1007/s10456-011-9207-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
31 Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia 2011;13:419-27. [PMID: 21532882 DOI: 10.1593/neo.101508] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
32 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sugimoto H, Nakamura M, Yoda H, Hiraoka K, Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H, Ozaki T. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov 2015;1:15010. [PMID: 27551445 DOI: 10.1038/cddiscovery.2015.10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
34 Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2014;Epub ahead of print. [PMID: 25068471 DOI: 10.1097/coc.0000000000000108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
35 Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. Biomed Res Int 2015;2015:681653. [PMID: 26161408 DOI: 10.1155/2015/681653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Nishiofuku H, Tanaka T, Marugami N, Sho M, Akahori T, Nakajima Y, Kichikawa K. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur Radiol 2016;26:1835-42. [PMID: 26385808 DOI: 10.1007/s00330-015-3999-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
38 Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
39 Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
40 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
41 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
42 Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J. RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J Clin Invest 2014;124:3601-11. [PMID: 25003191 DOI: 10.1172/JCI74134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
43 Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer 2013;108:1393-401. [PMID: 23511559 DOI: 10.1038/bjc.2013.96] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
44 Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-2796. [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412] [Cited by in Crossref: 166] [Cited by in F6Publishing: 90] [Article Influence: 27.7] [Reference Citation Analysis]
45 Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. [PMID: 20606091 DOI: 10.1200/jco.2010.28.1386] [Cited by in Crossref: 562] [Cited by in F6Publishing: 331] [Article Influence: 46.8] [Reference Citation Analysis]
46 Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 2018;118:1419-24. [PMID: 29695765 DOI: 10.1038/s41416-018-0068-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA. The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. Clin Colon Rectal Surg 2016;29:232-8. [PMID: 27582648 DOI: 10.1055/s-0036-1584292] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
48 Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. Int J Mol Sci 2020;21:E5840. [PMID: 32823989 DOI: 10.3390/ijms21165840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
49 An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21. [PMID: 20401474 DOI: 10.1007/s00228-010-0815-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
50 Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 2015;6:8255-60. [PMID: 25779664 DOI: 10.18632/oncotarget.3143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
51 Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology 2015;4:e1001217. [PMID: 26137397 DOI: 10.1080/2162402X.2014.1001217] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
52 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66 [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
53 Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J 3rd, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009;100:1842-5. [PMID: 19491904 DOI: 10.1038/sj.bjc.6605099] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
54 Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, Acedo P. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. J Clin Med 2021;10:566. [PMID: 33546207 DOI: 10.3390/jcm10040566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
56 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
57 Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 2014;43:343-9. [PMID: 24622062 DOI: 10.1097/MPA.0000000000000095] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
58 Hoque N, Hasan CM, Rana MS, Varsha A, Sohrab MH, Rahman KM. Fusaproliferin, a Fungal Mycotoxin, Shows Cytotoxicity against Pancreatic Cancer Cell Lines. Molecules 2018;23:E3288. [PMID: 30545017 DOI: 10.3390/molecules23123288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
59 Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Tsujino T, Tateishi K, Tada M, Omata M, Koike K. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 2010;103:1644-8. [PMID: 20978506 DOI: 10.1038/sj.bjc.6605955] [Cited by in Crossref: 99] [Cited by in F6Publishing: 129] [Article Influence: 8.3] [Reference Citation Analysis]
60 Seufferlein T, Ahn J, Krndija D, Lother U, Adler G, von Wichert G. Tumor biology and cancer therapy - an evolving relationship. Cell Commun Signal 2009;7:19. [PMID: 19678929 DOI: 10.1186/1478-811X-7-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
61 Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med. 2012;209:437-444. [PMID: 22351932 DOI: 10.1084/jem.20111923] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
62 Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int. 2011;2011:620601. [PMID: 21512581 DOI: 10.4061/2011/620601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
63 Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, Huang YF, Mao C, Tang JL. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8:e57528. [PMID: 23472089 DOI: 10.1371/journal.pone.0057528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
64 Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108:1052-1060. [PMID: 23422754 DOI: 10.1038/bjc.2013.69] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 12.8] [Reference Citation Analysis]
65 Wang ZP, Zhang HF, Zhang F, Hu BL, Wei HT, Guo YY. Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis. Eur J Clin Pharmacol 2015;71:517-24. [PMID: 25845654 DOI: 10.1007/s00228-015-1818-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Banerjee S, Saluja A. Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology 2015;15:S39-43. [PMID: 26122306 DOI: 10.1016/j.pan.2015.05.472] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
67 Fink DM, Steele MM, Hollingsworth MA. The lymphatic system and pancreatic cancer. Cancer Lett 2016;381:217-36. [PMID: 26742462 DOI: 10.1016/j.canlet.2015.11.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
68 Schlick K, Kiem D, Greil R. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Biomolecules 2021;11:1469. [PMID: 34680101 DOI: 10.3390/biom11101469] [Reference Citation Analysis]
69 Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med 2014;18:2235-51. [PMID: 25215932 DOI: 10.1111/jcmm.12361] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
70 Giardino A, Girelli R, Frigerio I, Regi P, Cantore M, Alessandra A, Lusenti A, Salvia R, Bassi C, Pederzoli P. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB (Oxford) 2013;15:623-7. [PMID: 23458679 DOI: 10.1111/hpb.12027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
71 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
72 Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 2012; 18(8): 736-745 [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
73 Jackson MW, Rusthoven CG, Fisher CM, Schefter TE. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther 2014;7:751-9. [PMID: 24876784 DOI: 10.2147/OTT.S49429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
74 Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
75 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
76 Gaschler-Markefski B, Sikken P, Heymach JV, Gottfried M, Mellemgaard A, Novello S, Gann CN, Barrueco J, Reck M, Hanna NH, Kaiser R. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. ESMO Open 2017;2:e000102. [PMID: 28761724 DOI: 10.1136/esmoopen-2016-000102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
77 Chames P, Kerfelec B, Baty D. Therapeutic antibodies for the treatment of pancreatic cancer. Scientific World Journal. 2010;10:1107-1120. [PMID: 20563534 DOI: 10.1100/tsw.2010.103] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
78 Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8(3): 297-304 [PMID: 26989465 DOI: 10.4251/wjgo.v8.i3.297] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
79 Kotasek D, Tebbutt N, Desai J, Welch S, Siu LL, McCoy S, Sun YN, Johnson J, Adewoye AH, Price T. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer 2011;11:313. [PMID: 21791058 DOI: 10.1186/1471-2407-11-313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
80 Strauss J, Alewine C, Figg WD, Duffy A. Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. Clin Transl Oncol 2016;18:653-9. [PMID: 26661112 DOI: 10.1007/s12094-015-1459-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
81 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
82 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
83 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
84 Zhao YD, Yang JK, Zhao AG. Advances in medical treatment of advanced pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(25): 2370-2376 [DOI: 10.11569/wcjd.v20.i25.2370] [Reference Citation Analysis]
85 Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Konishi H, Shiozaki A. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Sci Rep. 2017;7:5708. [PMID: 28720759 DOI: 10.1038/s41598-017-06137-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
86 Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
87 Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013;75:919-30. [PMID: 22882307 DOI: 10.1111/j.1365-2125.2012.04417.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 5.9] [Reference Citation Analysis]
88 Eklund L, Bry M, Alitalo K. Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol Oncol 2013;7:259-82. [PMID: 23522958 DOI: 10.1016/j.molonc.2013.02.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 8.4] [Reference Citation Analysis]
89 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
90 Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519 [PMID: 23901226 DOI: 10.3748/wjg.v19.i28.4511] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
91 Chiu JW, Wong H, Leung R, Pang R, Cheung TT, Fan ST, Poon R, Yau T. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014;19:937-50. [PMID: 25117068 DOI: 10.1634/theoncologist.2012-0131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
92 Chen Y, Wang L, Luo S, Hu J, Huang X, Li PW, Zhang Y, Wu C, Tian BL. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. Drug Des Devel Ther 2020;14:2945-57. [PMID: 32801636 DOI: 10.2147/DDDT.S261017] [Reference Citation Analysis]
93 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
94 Rice C, Huang LE. From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res 2010;3:9-16. [PMID: 21407995 DOI: 10.2147/CMR.S14812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
95 Zeng M, Feng Q, Lu M, Zhou J, Yang Z, Tang J. Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. Onco Targets Ther 2018;11:6633-46. [PMID: 30349297 DOI: 10.2147/OTT.S168418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 2011;29:1057-65. [PMID: 20306339 DOI: 10.1007/s10637-010-9413-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
97 Testini M, Gurrado A, Lissidini G, Venezia P, Greco L, Piccinni G. Management of mucinous cystic neoplasms of the pancreas. World J Gastroenterol 2010; 16(45): 5682-5692 [PMID: 21128317 DOI: 10.3748/wjg.v16.i45.5682] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
98 Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer. 2016;115:442-453. [PMID: 27441498 DOI: 10.1038/bjc.2016.215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
99 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
100 Zhang Z, Song J, Xie C, Pan J, Lu W, Liu M. Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials. AAPS J 2021;23:29. [PMID: 33580411 DOI: 10.1208/s12248-021-00556-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y, Kamei Y, Takahashi S, Namazu K, Umeyama Y. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial. Jpn J Clin Oncol. 2015;45:439-448. [PMID: 25647781 DOI: 10.1093/jjco/hyv011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
102 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
103 Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21. [PMID: 21364524 DOI: 10.1038/nrclinonc.2011.21] [Cited by in Crossref: 474] [Cited by in F6Publishing: 447] [Article Influence: 43.1] [Reference Citation Analysis]
104 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
105 Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015;6:18162-18173. [PMID: 26046796 DOI: 10.18632/oncotarget.4216] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 9.8] [Reference Citation Analysis]
106 Yang HH, Liu JW, Lee JH, Harn HJ, Chiou TW. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. Int J Mol Sci 2021;22:8125. [PMID: 34360896 DOI: 10.3390/ijms22158125] [Reference Citation Analysis]
107 Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014;74:379-387. [PMID: 24939212 DOI: 10.1007/s00280-014-2499-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
108 O’Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010;15:1310-1319. [PMID: 21148613 DOI: 10.1634/theoncologist.2010-0152] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
109 Mo J, Lin M, He B, Tan K, Jin C, Jiang H, Pan X, Lin W. Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. Oncol Lett 2017;14:6829-32. [PMID: 29181104 DOI: 10.3892/ol.2017.7058] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
110 Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192 [DOI: 10.5497/wjp.v4.i2.180] [Reference Citation Analysis]
111 Ghosn M, Kourie HR, Karak FE, Hanna C, Antoun J, Nasr D. Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol 2014; 20(9): 2352-2357 [PMID: 24605032 DOI: 10.3748/wjg.v20.i9.2352] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
112 Yasui H, Sato K, Takeyama Y, Kato T, Hashimoto H, Fukui Y, Yoshihisa N, Maeda M, Gonda H, Suzuki R. Carcinoma of unknown primary site treated with Carboplatin + Paclitaxel + bevacizumab + erlotinib and its maintenance chemotherapy. Case Rep Oncol 2014;7:583-90. [PMID: 25298764 DOI: 10.1159/000366268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
113 Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012;17:555-68. [PMID: 22426526 DOI: 10.1634/theoncologist.2011-0365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
114 Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015;33:4284-4292. [PMID: 26527777 DOI: 10.1200/jco.2015.62.8719] [Cited by in Crossref: 266] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
115 Delma MI. Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma? Cureus 2020;12:e10909. [PMID: 33194476 DOI: 10.7759/cureus.10909] [Reference Citation Analysis]
116 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
117 De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69:415-424. [PMID: 21800112 DOI: 10.1007/s00280-011-1704-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
118 Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol 2016;78:341-51. [PMID: 27329360 DOI: 10.1007/s00280-016-3079-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
119 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Mihaljevic AL, Michalski CW, Friess H, Kleeff J. Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg. 2010;395:295-308. [PMID: 20237938 DOI: 10.1007/s00423-010-0622-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
121 Yan HH, Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, Kim J, Kim MH, Hong SS. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 2014;5:9150-9168. [PMID: 25193856 DOI: 10.18632/oncotarget.2363] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
122 Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs. 2012;30:1203-1207. [PMID: 21526355 DOI: 10.1007/s10637-011-9673-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
123 Peng Z, Ji Z, Mei F, Lu M, Ou Y, Cheng X. Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway. PLoS One. 2013;8:e61457. [PMID: 23626687 DOI: 10.1371/journal.pone.0061457] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
124 Pothula SP, Xu Z, Goldstein D, Biankin AV, Pirola RC, Wilson JS, Apte MV. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br J Cancer. 2016;114:269-280. [PMID: 26766740 DOI: 10.1038/bjc.2015.478] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
125 Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol. 2012;2:6. [PMID: 22655256 DOI: 10.3389/fonc.2012.00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
126 Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial. Oncotarget 2015;6:12796-808. [PMID: 25918250 DOI: 10.18632/oncotarget.3473] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
127 Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010;16:1973-8. [PMID: 20215532 DOI: 10.1158/1078-0432.CCR-09-3182] [Cited by in Crossref: 76] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
128 Dittrich C, Königsberg R, Mittlböck M, Geissler K, Sahmanovic-Hrgovcic A, Pleiner-Duxneuner J, Czejka M, Buchner P. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Invest New Drugs 2019;37:127-38. [PMID: 29998365 DOI: 10.1007/s10637-018-0639-0] [Reference Citation Analysis]
129 Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010;15:683-94. [PMID: 20547589 DOI: 10.1634/theoncologist.2009-0235] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
130 Arias-Pinilla GA, Modjtahedi H. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel) 2021;13:1781. [PMID: 33917882 DOI: 10.3390/cancers13081781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012;30:1597-1606. [PMID: 21629990 DOI: 10.1007/s10637-011-9691-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
132 Seicean A, Petrusel L, Seicean R. New targeted therapies in pancreatic cancer. World J Gastroenterol 2015; 21(20): 6127-6145 [PMID: 26034349 DOI: 10.3748/wjg.v21.i20.6127] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
133 Li CM, Liu ZC, Bao YT, Sun XD, Wang LL. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World J Gastroenterol 2017; 23(41): 7478-7488 [PMID: 29151702 DOI: 10.3748/wjg.v23.i41.7478] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
134 Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol. 2010;31:351-357. [PMID: 20480409 DOI: 10.1007/s13277-010-0044-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
135 Sjoquist KM, Chin VT, Chantrill LA, O’Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM, Biankin AV, Yip D. Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol 2014; 20(24): 7849-7863 [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
136 Nalbantoglu S, Abu-Asab M, Tan M, Zhang X, Cai L, Amri H. Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis. OMICS 2016;20:442-7. [PMID: 27428255 DOI: 10.1089/omi.2016.0059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Wu Q, Tian Y, Zhang J, Zhang H, Gu F, Lu Y, Zou S, Chen Y, Sun P, Xu M, Sun X, Xia C, Chi H, Ying Zhu A, Tang D, Wang D. Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. Oncotarget 2017;8:102721-38. [PMID: 29254283 DOI: 10.18632/oncotarget.21970] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
138 Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010;9:2057-67. [PMID: 20587661 DOI: 10.1158/1535-7163.MCT-09-0768] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
139 Blum HE. Cell therapies and regenerative medicine. Hepatol Int 2014;8:158-65. [PMID: 26202498 DOI: 10.1007/s12072-013-9512-6] [Reference Citation Analysis]
140 Morin E, Sjöberg E, Tjomsland V, Testini C, Lindskog C, Franklin O, Sund M, Öhlund D, Kiflemariam S, Sjöblom T, Claesson-Welsh L. VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. J Pathol 2018;246:311-22. [PMID: 30027561 DOI: 10.1002/path.5141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
141 Echrish H, Madden LA, Greenman J, Maraveyas A. The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. Cancers (Basel) 2011;3:267-84. [PMID: 24212618 DOI: 10.3390/cancers3010267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
142 Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010;15:1205-1213. [PMID: 21045189 DOI: 10.1634/theoncologist.2010-0121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
143 Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236 [PMID: 24605022 DOI: 10.3748/wjg.v20.i9.2224] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
144 Craven KE, Gore J, Korc M. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Lett 2016;381:201-10. [PMID: 26723874 DOI: 10.1016/j.canlet.2015.11.047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
145 Lewis AR, Valle JW, McNamara MG. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? World J Gastroenterol 2016; 22(32): 7175-7185 [PMID: 27621566 DOI: 10.3748/wjg.v22.i32.7175] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
146 Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010;7:e1000307. [PMID: 20644708 DOI: 10.1371/journal.pmed.1000307] [Cited by in Crossref: 151] [Cited by in F6Publishing: 137] [Article Influence: 12.6] [Reference Citation Analysis]
147 Nakamura J, Tanaka T, Kitajima Y, Noshiro H, Miyazaki K. Methylation-mediated gene silencing as biomarkers of gastric cancer: A review. World J Gastroenterol 2014; 20(34): 11991-12006 [PMID: 25232236 DOI: 10.3748/wjg.v20.i34.11991] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
148 Bachet JB, Marechal R, Van Laethem JL. Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) 2011;3:675-99. [PMID: 24212636 DOI: 10.3390/cancers3010675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
149 Almhanna K, Philip PA. Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol 2011;12:111-25. [PMID: 21461670 DOI: 10.1007/s11864-011-0150-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
150 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
151 Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-1972. [PMID: 27358556 DOI: 10.2147/dddt.s105442] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
152 Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther 2011;12:169-80. [PMID: 21617380 DOI: 10.4161/cbt.12.3.16260] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
153 Smith JK, Chu QD, Tseng JF. Pancreatic Adenocarcinoma. In: Chu QD, Gibbs JF, Zibari GB, editors. Surgical Oncology. New York: Springer; 2015. pp. 283-313. [DOI: 10.1007/978-1-4939-1423-4_13] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
154 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
155 Zhu H, Li T, Du Y, Li M. Pancreatic cancer: challenges and opportunities. BMC Med 2018;16:214. [PMID: 30463539 DOI: 10.1186/s12916-018-1215-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
156 Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia 2011;13:980-90. [PMID: 22028623 DOI: 10.1593/neo.11916] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
157 Rebelo R, Polónia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 2021;14:280. [PMID: 33804613 DOI: 10.3390/ph14030280] [Reference Citation Analysis]
158 Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. Br J Cancer 2012;106:61-9. [PMID: 22134511 DOI: 10.1038/bjc.2011.526] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
159 Jackson DB, Sood AK. Personalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol 2011;8:735-41. [PMID: 21989071 DOI: 10.1038/nrclinonc.2011.151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
160 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 42.0] [Reference Citation Analysis]
161 Lin QJ, Yang F, Jin C, Fu DL. Current status and progress of pancreatic cancer in China. World J Gastroenterol 2015; 21(26): 7988-8003 [PMID: 26185370 DOI: 10.3748/wjg.v21.i26.7988] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 129] [Article Influence: 18.1] [Reference Citation Analysis]
162 Lu T, Prakash J. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer. Int J Nanomedicine 2021;16:6313-28. [PMID: 34552327 DOI: 10.2147/IJN.S279192] [Reference Citation Analysis]
163 Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, Dellinger MT, Castrillon DH, Brekken RA. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 2014;74:1032-44. [PMID: 24346431 DOI: 10.1158/0008-5472.CAN-13-2800] [Cited by in Crossref: 58] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
164 Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012;30:382-386. [PMID: 20803052 DOI: 10.1007/s10637-010-9526-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
165 Lei F, Xi X, Batra SK, Bronich TK. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:682-94. [PMID: 30796131 DOI: 10.1124/jpet.118.255786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
166 Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, Ni QX, Yu XJ, Liu L. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis 2019;22:15-36. [PMID: 30168025 DOI: 10.1007/s10456-018-9645-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 12.5] [Reference Citation Analysis]
167 Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol. 2012;23:2812-2820. [PMID: 22767582 DOI: 10.1093/annonc/mds134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
168 Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010;1:515-29. [PMID: 21317448 DOI: 10.18632/oncotarget.101006] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
169 Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28:585-593. [PMID: 20495549 DOI: 10.1038/nbt.1640] [Cited by in Crossref: 176] [Cited by in F6Publishing: 171] [Article Influence: 14.7] [Reference Citation Analysis]
170 Klotz LV, Eichhorn ME, Schwarz B, Seeliger H, Angele MK, Jauch KW, Bruns CJ. Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbecks Arch Surg 2012;397:569-78. [PMID: 22415155 DOI: 10.1007/s00423-012-0946-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
171 Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 2012;18:577-84. [PMID: 22142827 DOI: 10.1158/1078-0432.CCR-11-1387] [Cited by in Crossref: 74] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
172 Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011;17:2799-2806. [PMID: 21389100 DOI: 10.1158/1078-0432.ccr-10-2580] [Cited by in Crossref: 170] [Cited by in F6Publishing: 111] [Article Influence: 15.5] [Reference Citation Analysis]
173 Harris M, Bhuvaneshwar K, Natarajan T, Sheahan L, Wang D, Tadesse MG, Shoulson I, Filice R, Steadman K, Pishvaian MJ, Madhavan S, Deeken J. Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine. Pharmacogenet Genomics 2014;24:81-93. [PMID: 24401833 DOI: 10.1097/FPC.0000000000000015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
174 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Lee HS, Park SW. Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut Liver 2016;10:340-7. [PMID: 27114434 DOI: 10.5009/gnl15465] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
176 Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016;4:14. [PMID: 26981244 DOI: 10.1186/s40425-016-0119-z] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
177 Kutluk Cenik B, Ostapoff KT, Gerber DE, Brekken RA. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther 2013;12:992-1001. [PMID: 23729403 DOI: 10.1158/1535-7163.MCT-12-0995] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
178 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
179 Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X. The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J Gastrointest Oncol 2013;4:72-81. [PMID: 23451330 DOI: 10.3978/j.issn.2078-6891.2012.044] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
180 Wolpin BM, O’Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013;24:1792-1801. [PMID: 23448807 DOI: 10.1093/annonc/mdt066] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
181 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 24.7] [Reference Citation Analysis]
182 Vogl UM, Andalibi H, Klaus A, Vormittag L, Schima W, Heinrich B, Kafka A, Winkler T, Öhler L. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? BMC Cancer 2019;19:28. [PMID: 30621630 DOI: 10.1186/s12885-018-5240-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
183 Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M, Bodoky G. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol. 2015;26:921-927. [PMID: 25609246 DOI: 10.1093/annonc/mdv027] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 13.4] [Reference Citation Analysis]
184 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266-4276. [PMID: 22896693 DOI: 10.1158/1078-0432.ccr-11-3114] [Cited by in Crossref: 711] [Cited by in F6Publishing: 486] [Article Influence: 79.0] [Reference Citation Analysis]
185 Pericay Pijaume C, Escudero Emperador P, Bastús Piulats R, Campos Cervera JM, Esquerdo Galiana G, Gallén Castillo M, Alfaro Gamero J, Dotor Navarro E, Pisa Gatell A, Guasch Jordán I, Saigí Grau E; ACROSS group. Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. Clin Transl Oncol 2011;13:61-6. [PMID: 21239357 DOI: 10.1007/s12094-011-0618-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
186 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
187 Kotowski A, Ma WW. Emerging therapies in pancreas cancer. J Gastrointest Oncol 2011;2:93-103. [PMID: 22811835 DOI: 10.3978/j.issn.2078-6891.2011.002] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
188 Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy. Int J Mol Sci 2021;22:1170. [PMID: 33504013 DOI: 10.3390/ijms22031170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
189 Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol 2017;47:832-9. [PMID: 28541474 DOI: 10.1093/jjco/hyx075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
190 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
191 Usón PLS Junior, Tolentino FDS, Santos VM, Rother ET, Maluf FC. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. PLoS One 2020;15:e0230060. [PMID: 32130264 DOI: 10.1371/journal.pone.0230060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
192 Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18:273-80. [PMID: 23485622 DOI: 10.1634/theoncologist.2012-0339] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 8.2] [Reference Citation Analysis]
193 Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 2014;120:1780-6. [PMID: 24633933 DOI: 10.1002/cncr.28648] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
194 Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol 2016; 7(1): 27-43 [PMID: 26862489 DOI: 10.5306/wjco.v7.i1.27] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
195 Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol 2012;9:297-303. [PMID: 22330688 DOI: 10.1038/nrclinonc.2012.8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 10.5] [Reference Citation Analysis]
196 Chiu J, Yau T. Metastatic pancreatic cancer: are we making progress in treatment. Gastroenterol Res Pract. 2012;2012:898931. [PMID: 23304129 DOI: 10.1155/2012/898931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
197 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
198 Brunet LR, Hagemann T, Andrew G, Mudan S, Marabelle A. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology. 2016;5:e1112942. [PMID: 27141395 DOI: 10.1080/2162402x.2015.1112942] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
199 Zoratto F, Rossi L, Giordani E, Strudel M, Papa A, Tomao S. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumour Biol 2014;35:8471-82. [PMID: 25062724 DOI: 10.1007/s13277-014-2367-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
200 Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-64. [PMID: 23629668 DOI: 10.3390/ijms14059338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
201 Gysler SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. J Clin Invest 2021;131:147276. [PMID: 34060481 DOI: 10.1172/JCI147276] [Reference Citation Analysis]
202 Westphalen CB, Kukiolka T, Garlipp B, Hahn L, Fuchs M, Malfertheiner P, Reiser M, Kütting F, Heinemann V, Beringer A, Waldschmidt DT. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study. BMC Cancer 2020;20:155. [PMID: 32093649 DOI: 10.1186/s12885-020-6636-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Hu H, Han T, Zhuo M, Wu LL, Yuan C, Wu L, Lei W, Jiao F, Wang LW. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Sci Rep 2017;7:470. [PMID: 28352075 DOI: 10.1038/s41598-017-00288-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
204 Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci (Landmark Ed) 2011;16:803-14. [PMID: 21196204 DOI: 10.2741/3721] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
205 Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics 2010;9:695-704. [PMID: 20061307 DOI: 10.1074/mcp.M900234-MCP200] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
206 Park S, Kim D, Park JA, Kwon HJ, Lee Y. Targeting TM4SF5 with anti-TM4SF5 monoclonal antibody suppresses the growth and motility of human pancreatic cancer cells. Oncol Lett 2020;19:641-50. [PMID: 31897180 DOI: 10.3892/ol.2019.11134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers (Basel) 2021;13:799. [PMID: 33672917 DOI: 10.3390/cancers13040799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
208 Blum HE. Individualized medicine 2010. J Cell Mol Med 2010;14:2257-63. [PMID: 20731747 DOI: 10.1111/j.1582-4934.2010.01155.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014;14:471. [PMID: 24972449 DOI: 10.1186/1471-2407-14-471] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
210 Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res 2011;17:5822-32. [PMID: 21737511 DOI: 10.1158/1078-0432.CCR-11-1185] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
211 Xia NX, Qiu BA, Wen JY, Zhu JY, Liu P. Therapeutic effect of two-pathway chemotherapy in combination with gamma-ray stereotactic radiotherapy on local advanced pancreatic cancer: an analysis of 12 cases. Shijie Huaren Xiaohua Zazhi 2009; 17(18): 1888-1893 [DOI: 10.11569/wcjd.v17.i18.1888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
212 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
213 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
214 Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 2012;13:e427-36. [PMID: 23026828 DOI: 10.1016/S1470-2045(12)70275-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
215 Grapsa D, Saif MW, Syrigos K. Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? World J Gastrointest Oncol 2015; 7(10): 172-177 [PMID: 26483872 DOI: 10.4251/wjgo.v7.i10.172] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
216 Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol 2016; 22(31): 6987-7005 [PMID: 27610011 DOI: 10.3748/wjg.v22.i31.6987] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
217 Jhaveri DT, Zheng L, Jaffee EM. Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol 2014;41:559-75. [PMID: 25440603 DOI: 10.1053/j.seminoncol.2014.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
218 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
219 Korkeila EA. Advanced pancreatic cancer - how to choose an adequate treatment option. World J Gastroenterol 2015; 21(38): 10709-10713 [PMID: 26478662 DOI: 10.3748/wjg.v21.i38.10709] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
220 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 10.9] [Reference Citation Analysis]
221 Spratlin JL, Mulder KE. Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci 2011;12:5895-907. [PMID: 22016635 DOI: 10.3390/ijms12095895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
222 Oikonomou E, Koustas E, Goulielmaki M, Pintzas A. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 2014;5:11752-77. [PMID: 25361007 DOI: 10.18632/oncotarget.2555] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
223 Kahlert C, Fiala M, Musso G, Halama N, Keim S, Mazzone M, Lasitschka F, Pecqueux M, Klupp F, Schmidt T, Rahbari N, Schölch S, Pilarsky C, Ulrich A, Schneider M, Weitz J, Koch M. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Oncotarget 2014;5:12978-89. [PMID: 25483099 DOI: 10.18632/oncotarget.2651] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
224 Iglesias-Garcia J, Lariño-Noia J, Domínguez-Muñoz JE. When to puncture, when not to puncture: Pancreatic masses. Endosc Ultrasound 2014;3:91-7. [PMID: 24955338 DOI: 10.4103/2303-9027.123007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
225 Rios Perez MV, Dai B, Koay EJ, Wolff RA, Fleming JB. Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. Cureus 2015;7:e423. [PMID: 26848412 DOI: 10.7759/cureus.423] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 2013;4:56. [PMID: 23641216 DOI: 10.3389/fphar.2013.00056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]